Kallikrein-kinin system in chronic subdural haematomas: its roles in vascular permeability and regulation of fibrinolysis and coagulation

Hirosuke Fujisawa, Haruhide Ito, Shiro Kashiwagi, Sadahiro Nomura, Mikiko Toyosawa

Abstract
The kallikrein-kinin system is closely related to both fibrinolysis and coagulation, and bradykinin—the end product of this system—is a powerful mediator which increases vascular permeability. In the present study, to test the hypothesis that the kallikrein-kinin system plays a part in the aetiology of chronic subdural haematomas, components of this system (prekallikrein, high molecular weight kininogen (HMW-kininogen), and bradykinin), and those of the fibrinolytic and coagulation systems were measured at 134 haematoma sites in 119 patients. The activities of prekallikrein and HMW-kininogen in the haematomas were significantly lower than those in the plasma of the patients, and showed a parallel decrease. The bradykinin concentration in the haematoma was significantly higher than that in the plasma. These results indicate activation of the kallikrein-kinin system in chronic subdural haematomas. The activation of both fibrinolysis and coagulation was also shown, and there was a significant correlation between HMW-kininogen and plasminogen, fibrin/fibrinogen degradation products, or platelets in the haematomas. This suggests regulation of fibrinolysis and coagulation by the kallikrein-kinin system or mutual stimulation of these systems. In the outer membrane, perivascular haemorrhage, interstitial oedema, and leucocyte migration were evident microscopically, indicating an increase in vascular permeability. The protein concentration in the haematoma was significantly higher than that in the peripheral blood, indicating plasma exudation from the capillaries in the outer membrane. The activation of the kallikrein-kinin system, by increasing vascular permeability, may cause blood extravasation and plasma exudation from the capillaries into both the outer membrane and the haematoma cavity, resulting in enlargement of the haematoma.

Keywords: chronic subdural haematoma; kallikrein-kinin system; bradykinin; aetiology

Although chronic subdural haematomas comprise a common disease in the field of neurosurgery, their aetiology is not yet fully understood. The haematoma cavity is encapsulated by the inner and outer membranes, blood vessels being absent in the first but abundant in the second. Thus it has been suggested that repetitive haemorrhage from the outer membrane causes progressive enlargement of a haematoma.3 The haematoma fluid contains low fibrinogen and high fibrin/fibrinogen degradation product concentrations,4 and a high amount of tissue type plasminogen activator has been found in both the haematoma fluid and the blood vessels in the outer membrane.5 Thus increased fibrinolysis in the outer membrane (local hyperfibrinolysis) has been suggested to be a main aetiologial factor of chronic subdural haematomas.5-8 Indeed, repetitive haemorrhage from the outer membrane into the haematoma cavity, as the cause of haematoma enlargement, can be well explained by increased fibrinolysis. Some aspects which cannot be explained satisfactorily by increased fibrinolysis alone, however, remain unresolved—for example, (a) increased fibrinolysis alone cannot explain how the subdural membrane is produced; (b) factors regulating the fibrinolytic activity during the course of development of chronic subdural haematomas have not been fully determined; (c) the outer membrane, peri-vascular haemorrhage, interstitial oedema, and leucocyte migration are seen microscopically.9-10 In cases of subdural hygromas which develop into chronic subdural haematomas, the x ray absorption value of the subdural fluid on CT gradually increases.11-14 These findings seem to indicate an increase in vascular permeability of the outer membrane, although the factors responsible remain undetermined.

The kallikrein-kinin system consists basically of prekallikrein, kallikrein, high molecular weight kininogen (HMW-kininogen), and bradykinin (fig 1). Bradykinin—the end product of this system—is known to be a powerful mediator which increases vascular permeability and induces vasodilatation and leucocyte migration.15-17 Furthermore, through some common components, the kallikrein-kinin system is closely related not only to fibrinolysis but also to coagulation, which has also been suggested to play an important part in the origin and development of chronic subdural...
haematomas. In the present study, we measured the components of the kallikrein-kinin, fibrinolytic, and coagulation systems, and we discuss the possible contribution of the kallikrein-kinin system to the aetiology of chronic subdural haematomas.

**Materials and methods**

**PATIENT POPULATION AND SAMPLING OF HAEMATOMAS AND MEMBRANES**

Ninety male and 29 female patients with chronic subdural haematomas were studied. They ranged in age from 12 to 87 (mean 64-8) years, and had not received previous treatment for chronic subdural haematomas. One hundred and four of the patients had unilateral haematomas and 15 had bilateral haematomas. During surgery, the haematoma was aspirated by puncture through the dura mater with a disposable plastic syringe and the outer membrane attached to the dura mater was excised for histological examination. Peripheral blood samples were also taken from the patients.

**HISTOLOGICAL EXAMINATION**

A small piece of the dura mater along with the outer membrane was fixed in 10% formalin, processed routinely, and then embedded in paraffin. Thin sections (4 μm) were cut, stained with haematoxylin and eosin, and examined by light microscopy.

**MEASUREMENT OF THE KALLIKREIN-KININ SYSTEM**

The three major components of the kallikrein-kinin system were measured—namely, prekallikrein, HMW-kininogen, and bradykinin. For measurement of the prekallikrein and HMW-kininogen activities, haematoma samples were placed in siliconised vacuum tubes containing 3-8% sodium citrate. For measurement of bradykinin, samples were placed in siliconised vacuum tubes containing aprotinin, soybean trypsin inhibitor, protamine sulphate, and disodium EDTA. All tubes were placed in a box filled with ice until centrifuged at 3000 rpm for 10 minutes. Each supernatant was stored in a sealed polypropylene tube at −70°C until analysis. The prekallikrein and HMW-kininogen activities were measured by the one stage activated partial thromboplastin time method, with prekallikrein-deficient plasma and HMW-kininogen-deficient plasma respectively. These activities were expressed as percentages of those for normal plasma. Bradykinin was measured by radioimmunoassay.

**MEASUREMENT OF THE FIBRINOLYTIC AND COAGULATION SYSTEMS**

The major components of the fibrinolytic system—that is, fibrin/fibrinogen degradation products, tissue-type plasminogen activator, plasminogen, and α2 plasmin inhibitor, were measured. Plasminogen and α2 plasmin

---

**Figure 1** Functional diagram of the kallikrein-kinin system and its relation with the fibrinolytic and coagulation systems. HMW-kininogen = high molecular weight kininogen; t-PA = tissue-type plasminogen activator; FDP = fibrin/fibrinogen degradation products. → = activation; −→ = inhibition.
inhibitor were measured by the synthetic chromogenic substrate method, fibrin/fibrinogen degradation products by the latex agglutination method, and tissue-type plasminogen activator by enzyme linked immunosorbent assay. The coagulation system in chronic subdural haematomas was investigated by measurement of platelets, fibrinogen, antithrombin III, prothrombin time, and activated partial thromboplastin time, and by means of the thrombo test and heparplastin test. Fibrinogen was measured by the thrombin test, and antithrombin III by the synthetic chromogenic substrate method. The relations between the kallikrein-kinin, fibrinolytic, and coagulation systems were investigated.

MEASUREMENT OF BLOOD CELLS AND THE PROTEIN CONCENTRATION
White blood cells and erythrocytes, and the protein concentration in both a haematoma and peripheral blood were measured.

STATISTICS
Values are expressed as means (SEM). The statistical significance between two groups was assessed by unpaired Student’s t test. Bradykinin concentrations were analysed by the Wilcoxon signed rank test. Differences among three groups were tested by one way analysis of variance (ANOVA), followed by Scheffé’s F test for multiple comparisons. Correlations between different variables were examined by Pearson’s linear regression.

Results
HISTOLOGICAL FINDINGS IN THE OUTER MEMBRANE
Morphologically, the outer membranes comprised granulation tissue consisting of collagen fibrils, fibroblasts, and abundant capillaries (macropapillaries or sinusoids). Perivascular haemorrhage, interstitial oedema, and leucocyte migration were often seen (fig 2). Some of the capillaries were in direct contact with the haematoma cavity, and some white blood cells and erythrocytes seemed to be passing through the capillaries into the haematoma cavity (fig 2C). Although the migration of only eosinophils is shown in fig 2, neutrophils, lymphocytes, haemosiderin containing macrophages, and plasma cells were also present in some specimens. Among leucocytes, eosinophils were present most often and were most easily identified on light microscopy. To compare the amounts of leucocytes in the outer membrane and a haematoma, eosinophils in the outer membrane were counted in 24 membrane specimens at a magnification of ×40, and then the outer membranes were divided into three groups according to the number of eosinophils present: no eosinophils (n = 8); a few eosinophils (cell count ≤ 60; n = 5); many eosinophils (cell count ≥ 100; n = 11).

THE KALLIKREIN-KININ SYSTEM
Prekallikrein activity in the haematomas was 54-6 (2-6)% significantly lower than that in the plasma of the patients (79-4 (2-7)%); fig...
Kallikrein-kinin system in chronic subdural haematoma: its roles in vascular permeability and regulation of fibrinolysis and coagulation

...activity in the haematomas was 42.4 (2.4)%, significantly lower than that in the patients' plasma (79.2 (3.2)%; fig 3B). Prekallikrein and HMW-kininogen activities in the haematomas showed a parallel decrease and a significant correlation (fig 3C). The bradykinin concentration in the haematomas (63.9 (12.1 pg/ml)) was significantly higher than that in the plasma (36.4 (5.6 pg/ml; fig 3D)).

FIBRINOLYSIS AND COAGULATION

The plasminogen and α2 plasmin inhibitor concentrations in the haematomas were significantly lower than those in the peripheral blood of the patients (table 1). The fibrin/ fibrinogen degradation products and tissue-type plasminogen activator concentrations in the haematomas were significantly higher than those in the peripheral blood. As to the relation between the kallikrein-kinin and fibrinolytic systems, there was a significant correlation between HMW-kininogen and plasminogen or fibrin/fibrinogen degradation products (fig 4A, 4B).

The haematoma contained an extremely low level of fibrinogen (table 1). Platelet count and antithrombin III in the haematoma were significantly lower than those in the peripheral blood. Prothrombin time and activated partial thromboplastin time in the haematoma were significantly prolonged, and results of the thrombo-test and heparplastin test for the haematoma gave lower values than for peripheral blood. There was a significant correlation between HMW-kininogen and platelets (fig 4C).

BLOOD CELLS AND PROTEIN CONCENTRATIONS

The haematoma contained white blood cells and erythrocytes (table 2). The number of eosinophils in the haematoma increased in parallel with the number in the outer membrane (table 3). The protein concentration in the peripheral blood of the patient was 6.3 (0.1 g/dl), being within the normal range. By contrast, the protein concentration in the haematoma was 8.4 (0.4 g/dl), significantly higher than that in the peripheral blood (table 2).

Discussion

ACTIVATION OF THE KALLIKREIN-キンINC SYSTEM IN CHRONIC SUBDURAL HAEMATOMAS

The kallikrein-kinin system consists of prekallikrein, kallikrein, HMW-kininogen, and bradykinin (fig 1). Prekallikrein is present in plasma as an inactive precursor and is transformed into kallikrein by activated coagulation factor XII (Hageman factor). There are two types of kininogen in human plasma; HMW-kininogen and low molecular weight kininogen. Kallikrein prefers HMW-kininogen as a substrate, converting it to bradykinin. Activation of the kallikrein-kinin system is an extremely rapid process, and the half-life of bradykinin is very short (about 17 seconds) due to the action of kininas. If reduction of both prekallikrein and HMW-kininogen

---

**Figure 3**  (A) Prekallikrein activities in the haematoma and plasma (**p** < 0.001; Student's t test). (B) HMW-kininogen activities in the haematoma and plasma (**p** < 0.001; Student's t test). (C) Correlation between prekallikrein and HMW-kininogen activities in the haematoma (62 paired observations. r = 0.72, P < 0.0001; Pearson's linear regression). (D) Bradykinin concentrations in the haematoma and plasma (**p** < 0.05; Wilcoxon signed rank test).

**Figure 4**  (A) Correlation between HMW-kininogen and plasminogen in the haematoma (46 paired observations. r = 0.45, P < 0.005; Pearson's linear regression). (B) Correlation between HMW-kininogen and FDP in the haematoma (54 paired observations. r = 0.56, P < 0.0001 by Pearson's linear regression). (C) Correlation between HMW-kininogen and platelets in the haematoma (43 paired observations. r = 0.56, P < 0.0001 by Pearson's linear regression).
Table 1 Components of the fibrinolytic and coagulation systems

<table>
<thead>
<tr>
<th></th>
<th>Haematomas</th>
<th>Peripheral blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDP (μg/ml)</td>
<td>1078 (72)** (n = 114)</td>
<td>7-0 (8-9) (n = 48)</td>
</tr>
<tr>
<td>Plasminogen (%)</td>
<td>50-1 (3-4)** (n = 51)</td>
<td>84-7 (4-1) (n = 41)</td>
</tr>
<tr>
<td>t-PA (ng/ml)</td>
<td>10-1 (6-0)** (n = 134)</td>
<td>37-0 (2-0) (n = 79)</td>
</tr>
<tr>
<td>a2 PI (%)</td>
<td>30-0 (2-5)** (n = 50)</td>
<td>62-3 (3-0) (n = 41)</td>
</tr>
<tr>
<td>Platelets (&lt; 10^10/ml)</td>
<td>9-9 (1-5)** (n = 48)</td>
<td>25-0 (1-6) (n = 48)</td>
</tr>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>10-4 (8-2)** (n = 53)</td>
<td>278-7 (18-9) (n = 45)</td>
</tr>
<tr>
<td>PT (s)</td>
<td>189-3 (1-5)** (n = 53)</td>
<td>12-5 (0-2) (n = 45)</td>
</tr>
<tr>
<td>APTT (s)</td>
<td>195-9 (2-9)** (n = 54)</td>
<td>35-0 (1-0) (n = 45)</td>
</tr>
<tr>
<td>Thrombo test (%)</td>
<td>25-1 (2-1)** (n = 30)</td>
<td>66-1 (3-9) (n = 27)</td>
</tr>
<tr>
<td>Hepaplastin test (%)</td>
<td>24-9 (2-0)** (n = 53)</td>
<td>110-1 (2-5) (n = 40)</td>
</tr>
<tr>
<td>AT III (%)</td>
<td>42-6 (1-9)** (n = 49)</td>
<td>99-7 (2-4) (n = 41)</td>
</tr>
</tbody>
</table>

FDP = fibrin/fibrinogen degradation products; t-PA = tissue-type plasminogen activator; a2 PI = a2 plasmin inhibitor; PT = prothrombin time; APTT = activated partial thromboplastin time; AT III = antithrombin III. **P < 0.001 v peripheral blood (Student's t test).

Table 2 Blood cells and protein concentrations

<table>
<thead>
<tr>
<th></th>
<th>Haematomas</th>
<th>Peripheral blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cells (ml)</td>
<td>5781 (1068) (n = 52)</td>
<td>6994 (361) (n = 48)</td>
</tr>
<tr>
<td>Erythrocytes (&lt; 10^10/ml)</td>
<td>303 (18)** (n = 53)</td>
<td>383 (7) (n = 48)</td>
</tr>
<tr>
<td>Protein (g/dl)</td>
<td>8-4 (2-0)** (n = 61)</td>
<td>6-0 (1-0) (n = 39)</td>
</tr>
</tbody>
</table>

***P < 0.001 v peripheral blood (Student's t test).

Table 3 Eosinophils in the outer membrane and haematomas

<table>
<thead>
<tr>
<th>Eosinophils:</th>
<th>Haematomas (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>77 (29) (n = 8)</td>
</tr>
<tr>
<td>Few (cell count &lt; 60)</td>
<td>592 (357) (n = 5)</td>
</tr>
<tr>
<td>Many (cell count &gt; 100)</td>
<td>5202 (1246) (n = 11)</td>
</tr>
</tbody>
</table>

*P < 0.05, ***P < 0.001 by ANOVA, followed by Scheffe's test for multiple comparisons.

occursthis could be regarded as indirect proof of activation of this system. The prekallikrein and HMW-kininogen activities in normal plasma are 102 (23)% and 99 (25)% respectively. In the present study, plasma prekallikrein and HMW-kininogen activities in the patients remained within the normal range, whereas the corresponding activities in the haematomas were significantly lower and showed a parallel decrease. Furthermore, despite its short half life, the concentration of bradykinin in the haematomas was significantly higher than that in the plasma. These results indicate that local activation of the kallikrein-kinin system occurs in chronic subdural haematomas.

INCREASE OF VASCULAR PERMEABILITY IN CHRONIC SUBDURAL HAEMATOMAS

The haematoma fluid contains white blood cells and erythrocytes. Ito et al. demonstrated daily haemorrhage from the outer membrane into the haematoma cavity by the chromium-51 labelled erythrocyte infusion method. The present study disclosed a parallel increase of eosinophils in both the outer membrane and the haematomas. Thus the blood cells in the haematomas must extravasate from the capillaries in the outer membrane, and it may be due to an increase in vascular permeability. In the outer membrane, perivascular haemorrhage, interstitial oedema, and leukocyte migration, which also indicate an increase in vascular permeability, are often evident microscopically. Ultrastructural studies of the outer membrane have shown gaps between capillary endothelial cells at the sites of leakage of erythrocytes and plasma, which are observed microscopically as perivascular haemorrhage and interstitial oedema respectively. These endothelial gaps are known to be anatomical substrata for the increase in vascular permeability.

The protein concentration in the haematomas was significantly higher than that in the peripheral blood, and similar to that in the fluid exudate of inflamed tissue. It has been reported that chronic subdural haematomas show changes in density on CT and in signal intensity on MRI, which has been attributed to rebleeding into the haematoma cavity or a chemical change in haemoglobin. Although bleeding or haemolysis may be partly responsible for the high protein concentration in the haematoma, we speculate that plasma exudation from the capillaries in the outer membrane due to an increase in vascular permeability may also play a part. For example, in cases of subdural hygromas, the x ray absorption values on CT or signal intensity on T1 weighted MRI of the subdural fluid gradually increase. Subdural hygromas contain a high concentration of protein, and histological examinations have shown that they have the same kind of subdural membrane as that seen in chronic subdural haematomas. Fluid exudation due to increased vascular permeability of the membrane may therefore play an important part in creating the high protein concentration and in increasing the volume of subdural hygromas, and the same may be the case in chronic subdural haematomas. The question arises, however, as to what causes the increase in vascular permeability.

Many factors have been reported to increase vascular permeability in reparative or inflammatory tissue—for example, bradykinin, histamine, serotonin, and prostaglandins. As the outer membrane of chronic subdural haematomas is a kind of reparative tissue, these factors could be activated. Among these factors, bradykinin is known to be the most powerful mediator for increasing vascular permeability. For example, its effect on vascular permeability is at least 20 times as strong as that of histamine or prostaglandins. Although serotonin induces effects similar to histamine in rodents, its role in humans has not been established. Thus we speculate that bradykinin generated by activation of the kallikrein-kinin system is the main factor responsible for increasing vascular permeability in chronic subdural haematomas. An important role of the kallikrein-kinin system in the pathogeneses of various pathological conditions through increasing vascular permeability has also been reported.

RELATION OF THE KALLIKREIN-KININ SYSTEM WITH FIBRINOLOGY AND COAGULATION, AND PUTATIVE AETOLOGY OF CHRONIC SUBDURAL HAEMATOMAS

The present study demonstrated low plasminogen and a2 plasmin inhibitor, and high fibrin/fibrinogen degradation products and...
Kallikrein-kinin system in chronic subdural haematomas: its roles in vascular permeability and regulation of fibrinolysis and coagulation

Figure 5 Putative aetiology of chronic subdural haematomas. (A) Formation of the subdural membrane. (B) Blood extravasation and plasma exudation. (C) Haemostasis. (D) Rebleeding.

Figure 5 illustrates the putative aetiology of chronic subdural haematomas. Morphologically, the outer membrane is composed of granulation tissue, and thus some reactive responses may occur in the subdural space during the early stage, leading to the production of the highly vascularised outer membrane (fig 5A). This view is supported by the fact that chronic subdural haematomas occasionally develop from acute subdural haematomas. In these cases, fibroblasts and capillaries proliferate in the fibrin clots to form the subdural granulation tissue. Fibrin is known to be produced not only in extravasated blood but also in fluid exudates, and forms a matrix for migrating fibroblasts. Thus any foreign substance in the subdural space, as well as small amounts of subdural haemorrhage or fluid, may stimulate the formation of the membrane. Then, blood extravasation, plasma exudation, and leucocyte migration into both the membrane and the haematoma cavity may occur due to an increase in vascular permeability (fig 5B). This

...plasmin was initially identified in 1965 as the principal plasminogen activator of the human plasma system. It is a serine protease that cleaves the amino-terminal 92 residue fragment of plasminogen, generating active plasmin. Plasminogen activators are divided into two major classes: tissue-type plasminogen activators and urokinase-type plasminogen activators. Tissue-type plasminogen activators are secreted by a variety of cells in response to injury, whereas urokinase-type plasminogen activators are produced by the kidney. Plasmin is a serine protease that degrades fibrin but also degrades a number of other proteins, including fibrinogen, fibronectin, and von Willebrand factor.

...the reactivity of the fibrinolytic system in chronic subdural haematomas. Kawakami et al. suggested that excessive activation of the fibrinolytic system in subdural haematomas may lead to the development of chronic subdural haematomas. This is supported by the fact that chronic subdural haematomas often develop from acute subdural haematomas. In these cases, fibroblasts and capillaries proliferate in the fibrin clots to form the subdural granulation tissue. Fibrin is known to be produced not only in extravasated blood but also in fluid exudates, and forms a matrix for migrating fibroblasts. Thus any foreign substance in the subdural space, as well as small amounts of subdural haemorrhage or fluid, may stimulate the formation of the membrane. Then, blood extravasation, plasma exudation, and leucocyte migration into both the membrane and the haematoma cavity may occur due to an increase in vascular permeability (fig 5B). This...
increase may be caused by the kallikrein-kinin system as discussed earlier. Then platelets may aggregate and fibrin clots may be formed in the endothelial gaps of capillaries, some of which are in direct contact with the haemato ma cavity. However, the clots may be easily broken down, however, due to local hyperfibrinolysis (fig SC). This view is supported by the fact that most of the fibrin/fibrinogen degradation products in the haemato ma fluid are derived from degradation of fibrin (not fibrinogen).

In the present study, showing the activation of the kallikrein-kinin system and the close relation of this system with fibrinolysis and coagulation, we have suggested that the kallikrein-kinin system plays an important part in the aetiology of chronic subdural haematomas. There may be some controversy, however, with regard to whether the activation of this system in chronic subdural haematomas is merely an epiphenomenon or whether this activation is sufficient to exert important biological effects in chronic subdural haematomas.

Further pharmacological investigations involving specific inhibitors (for example, bradykinin antagonists or kallikrein blockers) will help to resolve these issues and will be of interest for both experimental and clinical application.